NetraMark Achieves Major FDA Milestone

Executive Summary

• NetraMark completed a Critical Path Innovation Meeting (CPIM) with the U.S. FDA, receiving feedback on its NetraAI platform and potential regulatory pathways.
• The FDA suggested exploring the Model‑Informed Drug Development (MIDD) Paired Meeting Program for further dialogue alongside pharmaceutical sponsors.
• Management highlighted that the discussion validates NetraAI’s explainable AI approach and positions it as a tool to improve trial design, statistical power, and risk reduction.

Key Details

• Meeting Type: Critical Path Innovation Meeting (CPIM) – non‑regulatory, scientific exchange with FDA.
• Platform Discussed: NetraAI – an explainable AI/ML platform for predictive enrichment in clinical trials.
• FDA Feedback Highlights:
• Validation of NetraAI’s approach to pre‑specified, a‑controlled predictive enrichment and control of Type I error.
• Distinction of NetraAI from complex adaptive designs, Bayesian methods, and simulation‑based approaches excluded from MIDD eligibility.
• Potential applications: targeted inclusion/exclusion criteria, pre‑specified stratification in SAPs, trial simulations for power/effect size assessment.
• Regulatory Pathway Suggested: Exploration of the FDA’s Model‑Informed Drug Development (MIDD) Paired Meeting Program as a next step for formal regulatory dialogue.
• Management Comments:
• Dr. Joseph Geraci emphasized NetraAI’s novel mathematical substrate and its ability to identify stable, clinically interpretable subgroups in small, heterogeneous datasets.
• Dr. Luca Pani noted three years of work aligning NetraAI with FDA guidance on enrichment strategies, model risk, and AI/ML credibility.
• CEO George Achilleos described the CPIM as a strategic asset that can help sponsors design stronger Phase 2/3 programs and de‑risk pivotal trials.
• Forward‑Looking Statements: The release contains expectations regarding future regulatory engagement, potential trial applications, and anticipated benefits to sponsors, all subject to risk factors and uncertainties.

Notable Quotes

“FDAs engagement in scientific discussion about our approach reinforces our belief that explainability, reproducibility, and scientific rigor are the foundations upon which next‑generation AI for drug development must be built.” – Dr. Joseph Geraci, Founder & Chief Scientific & Technology Officer

“Exploring the MIDD program will allow us to formalize this dialogue within an active drug development program and demonstrate how explainable AI—used appropriately—can de‑risk pivotal trials.” – Dr. Luca Pani, Chief Regulatory and Innovation Officer

“The CPIM discussion is an important step forward for NetraMark… sponsors can consider NetraAI to target the right patients, improve statistical power and reduce trial risk.” – George Achilleos, CEO